Cargando…
BluePen Biomarkers LLC: integrated biomarker solutions
BluePen Biomarkers provides a unique comprehensive multi-omics biomarker discovery and validation platform. We can quantify, integrate and analyze genomics, proteomics, metabolomics and lipidomics biomarkers, alongside clinical data, demographics and other phenotypic data. A unique bio-inspired sign...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137845/ https://www.ncbi.nlm.nih.gov/pubmed/28031971 http://dx.doi.org/10.4155/fsoa-2016-0031 |
_version_ | 1782471965384114176 |
---|---|
author | Blair, Ian A Mesaros, Clementina Lilley, Patrick Nunez, Matthew |
author_facet | Blair, Ian A Mesaros, Clementina Lilley, Patrick Nunez, Matthew |
author_sort | Blair, Ian A |
collection | PubMed |
description | BluePen Biomarkers provides a unique comprehensive multi-omics biomarker discovery and validation platform. We can quantify, integrate and analyze genomics, proteomics, metabolomics and lipidomics biomarkers, alongside clinical data, demographics and other phenotypic data. A unique bio-inspired signal processing analytic approach is used that has the proven ability to identify biomarkers in a wide variety of diseases. The resulting biomarkers can be used for diagnosis, prognosis, mechanistic studies and predicting treatment response, in contexts from core research through clinical trials. BluePen Biomarkers provides an additional groundbreaking research goal: identifying surrogate biomarkers from different modalities. This not only provides new biological insights, but enables least invasive, least-cost tests that meet or exceed the predictive quality of current tests. |
format | Online Article Text |
id | pubmed-5137845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Future Science Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-51378452016-12-28 BluePen Biomarkers LLC: integrated biomarker solutions Blair, Ian A Mesaros, Clementina Lilley, Patrick Nunez, Matthew Future Sci OA Company Profile BluePen Biomarkers provides a unique comprehensive multi-omics biomarker discovery and validation platform. We can quantify, integrate and analyze genomics, proteomics, metabolomics and lipidomics biomarkers, alongside clinical data, demographics and other phenotypic data. A unique bio-inspired signal processing analytic approach is used that has the proven ability to identify biomarkers in a wide variety of diseases. The resulting biomarkers can be used for diagnosis, prognosis, mechanistic studies and predicting treatment response, in contexts from core research through clinical trials. BluePen Biomarkers provides an additional groundbreaking research goal: identifying surrogate biomarkers from different modalities. This not only provides new biological insights, but enables least invasive, least-cost tests that meet or exceed the predictive quality of current tests. Future Science Ltd 2016-06-09 /pmc/articles/PMC5137845/ /pubmed/28031971 http://dx.doi.org/10.4155/fsoa-2016-0031 Text en © Ian A Blair This work is licensed under a Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Company Profile Blair, Ian A Mesaros, Clementina Lilley, Patrick Nunez, Matthew BluePen Biomarkers LLC: integrated biomarker solutions |
title | BluePen Biomarkers LLC: integrated biomarker solutions |
title_full | BluePen Biomarkers LLC: integrated biomarker solutions |
title_fullStr | BluePen Biomarkers LLC: integrated biomarker solutions |
title_full_unstemmed | BluePen Biomarkers LLC: integrated biomarker solutions |
title_short | BluePen Biomarkers LLC: integrated biomarker solutions |
title_sort | bluepen biomarkers llc: integrated biomarker solutions |
topic | Company Profile |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137845/ https://www.ncbi.nlm.nih.gov/pubmed/28031971 http://dx.doi.org/10.4155/fsoa-2016-0031 |
work_keys_str_mv | AT blairiana bluepenbiomarkersllcintegratedbiomarkersolutions AT mesarosclementina bluepenbiomarkersllcintegratedbiomarkersolutions AT lilleypatrick bluepenbiomarkersllcintegratedbiomarkersolutions AT nunezmatthew bluepenbiomarkersllcintegratedbiomarkersolutions |